Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 1/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 12/20 | 0.37 |
| ▸ | ITGAV | P06756 | 12/20 | 0.37 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.37 |
| ▸ | ITGB6 | P18564 | 2/20 | 0.35 |
| ▸ | ITGB5 | P18084 | 2/20 | 0.35 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.35 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.34 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5221123 | 0.75 | CXCR4 (0.39) | NNMTITGB3ITGAVCXCR4ITGB6 | |
| SCHEMBL21284330 | 0.70 | ITGB3 (0.41) | NNMTITGB3ITGAVCXCR4ITGB6 | |
| SCHEMBL30474583 | 0.70 | UHRF1 (0.53) | NNMTITGB3ITGAVCXCR4ITGB6 | |
| SCHEMBL18202389 | 0.70 | ITGB3 (0.39) | NNMTITGB3ITGAVCXCR4ITGB6 | |
| SCHEMBL8168165 | 0.70 | ITGAV (0.39) | NNMTITGB3ITGAVCXCR4ITGB6 | |
| SCHEMBL279665 | 0.70 | UHRF1 (0.53) | NNMTITGB3ITGAVCXCR4ITGB6 | |
| SCHEMBL1810290 | 0.70 | ITGB3 (0.39) | NNMTITGB3ITGAVCXCR4ITGB6 | |
| SCHEMBL325029 | 0.70 | ITGB3 (0.39) | NNMTITGB3ITGAVCXCR4ITGB6 | |
| SCHEMBL38950 | 0.69 | NNMT (0.44) | NNMTCXCR4UHRF1 | |
| SCHEMBL13456 | 0.69 | NNMT (0.37) | NNMTITGB3ITGAVUHRF1OR51E2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060234997-A1 | Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia | WARNER-LAMBERT COMPANY LLC | 2006-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060234997-A1 | Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia | PTGDR, GRIN2A, PTGDR2 | NNMT 870/4885ITGB3 4644/4885ITGAV 4258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.